Regeneron Pharmaceuticals Inc (REGN)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$16.65 (-1.74%)Past Day

About

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Key Insights

  • Share Price

    $941.43

  • Market Cap

    $103.78 Billion

  • Total Outstanding Shares

    108.42 Million Shares

  • Total Employees

    14,176

  • Dividend

    No dividend

  • IPO Date

    April 2, 1991

  • SIC Description

    Pharmaceutical Preparations

  • Homepage

    https://www.regeneron.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2023 to June 30, 2024
MetricValue
Net Cash Flow From Operating Activities$4.07 Billion
Net Cash Flow, Continuing$-20.70 Million
Net Cash Flow From Financing Activities, Continuing$-1.28 Billion
Net Cash Flow$-21.50 Million
Net Cash Flow From Investing Activities, Continuing$-2.81 Billion
Net Cash Flow From Investing Activities$-2.81 Billion
Exchange Gains/Losses$800000.00
Net Cash Flow From Operating Activities, Continuing$4.07 Billion
Net Cash Flow From Financing Activities$-1.28 Billion

Income Statement

July 1, 2023 to June 30, 2024
MetricValue
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Other Operating Expenses$2.06 Billion
Nonoperating Income/Loss$682.30 Million
Basic Average Shares$214.20 Million
Revenues$13.49 Billion
Operating Income/Loss$3.90 Billion
Income/Loss From Continuing Operations Before Tax$4.59 Billion
Research and Development$4.70 Billion
Diluted Average Shares$228.70 Million
Net Income/Loss Available To Common Stockholders, Basic$4.32 Billion
Income/Loss From Continuing Operations After Tax$4.32 Billion
Net Income/Loss Attributable To Parent$4.32 Billion
Operating Expenses$9.58 Billion
Basic Earnings Per Share$40.32
Net Income/Loss$4.32 Billion
Selling, General, and Administrative Expenses$2.83 Billion
Income Tax Expense/Benefit$265.50 Million
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Earnings Per Share$37.77
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Costs And Expenses$9.58 Billion
Benefits Costs and Expenses$8.90 Billion

Balance Sheet

July 1, 2023 to June 30, 2024
MetricValue
Other Non-current Assets$15.90 Billion
Noncurrent Liabilities$4.37 Billion
Other Current Liabilities$2.95 Billion
Current Assets$19.08 Billion
Assets$36.09 Billion
Equity Attributable To Noncontrolling Interest$0.00
Liabilities$7.88 Billion
Intangible Assets$1.10 Billion
Accounts Payable$561.70 Million
Equity$28.21 Billion
Liabilities And Equity$36.09 Billion
Noncurrent Assets$17.01 Billion
Other Current Assets$16.21 Billion
Inventory$2.87 Billion
Current Liabilities$3.51 Billion
Equity Attributable To Parent$28.21 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
News ArticlesAbout UsPrivacy Policy & Cookies Information

ⓒ2024 Financhle. All Rights Reserved.